## Hans de reu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7238442/publications.pdf

Version: 2024-02-01

		1163117	1281871	
11	233	8	11	
papers	citations	h-index	g-index	
13	13	13	449	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Preexisting memory CD4 T cells in na $\tilde{\rm A}$ ve individuals confer robust immunity upon hepatitis B vaccination. ELife, 2022, $11$ , .	6.0	11
2	Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner. Cytotherapy, 2022, , .	0.7	4
3	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Frontiers in Immunology, 2022, 13, 734256.	4.8	2
4	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine, 2022, 20, 124.	4.4	21
5	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. Cancers, 2020, 12, 256.	3.7	12
6	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. Journal of Neuroinflammation, 2019, 16, 167.	7.2	20
7	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. Frontiers in Immunology, 2018, 9, 2503.	4.8	29
8	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. Frontiers in Immunology, 2018, 9, 658.	4.8	38
9	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget, 2018, 9, 27797-27808.	1.8	17
10	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. Cancer Immunology Research, 2017, 5, 710-715.	3.4	36
11	Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget, 2015, 6, 44123-44133.	1.8	39